Introduction
There has recently been interest in the 620W allele of the hematopoeitic-specific intracellular protein tyrosine phosphatase PTPN22 (OMIM# 600716). This allele is present at a frequency of 8 -16% in North American individuals of European descent. 1 -4 The functional role of this R620W
amino-acid substitution remains unclear at this time; in vitro, the presence of the 620W allele decreases the binding affinity of an SH3 domain of the lymphoid-specific phosphatase (LYP) encoded by PTPN22. 1, 2 In terms of the function of LYP, RNAi knockdown of PTPN22 results in increased NF-kB activity in the Jurkat T-cell line, 2 and a targeted null allele of PTPN22 in mice is associated with enhanced activation of the T-cell receptor. 5 Given these data on LYP function, several lines of evidence suggest that the 620W allele of PTPN22 may lower the threshold of T-cell activation and hence may have a role in susceptibility to inflammatory diseases. 1, 2, 5 An association between the 620W allele and susceptibility to disease was first noted in subjects with Type 1 diabetes mellitus (T1D) 1 and prompted us to assess the possible role of the 620W allele in two other inflammatory diseases: Crohn's disease (CD) which affects the gastrointestinal tract and multiple sclerosis (MS) which consists of inflammatory demyelinating episodes in the central nervous system. T cells play an important role in both CD and MS, suggesting a pathophysiological rationale for a possible role of PTPN22 620W in conferring susceptibility to these diseases. 6, 7 Since the original report of association with T1D, additional associations have been described with susceptibility to rheumatoid arthritis (RA), 2 systemic lupus erythematosus (SLE), 4 and autoimmune thyroiditis (AIT). 8, 9 While it is possible that the 620W allele may be associated with susceptibility to several different inflammatory diseases, an accurate estimate of the extent of the disease risk attributable to this allele awaits further replication efforts in each disease. Genetic data from some linkage studies also suggested that the area of chromosome 1 in which PTPN22 is found (1p13) is contained in linkage peaks for CD 10 and MS. 
Materials and methods

Subjects
All affected MS subjects have a diagnosis of MS according to the Poser criteria 21 and are of European descent. All individuals in the UK cohort gave written informed consent for genetic analysis. The study has ethical approval from the Anglia and Oxford Multicentre Ethics Committee. All affected CD subjects fulfill clinical criteria for CD 22 and were consented using a common protocol approved by the institutional review boards of each institution contributing samples in Québec. This collection consists of 169 trios as well as an independent 249 subjects with CD and their 207 matched control subjects. No significant heterogeneity was noted between the allele frequencies in the two CD sample collections or the novel and published MS collections.
Genotytping
All samples were genotyped for rs2476601 using the Sequenom MassArray system as described previously. 23 The genotyping success rate was 97.3% for the MS samples and 93.0% for the CD samples. Genotypes did not deviate from Hardy -Weinberg Equilibrium (HWE; P-value 40.01).
there was a Mendelian error (ME) rate of 0.002 in the MS sample and 0 in the CD sample.
Statistical analysis
Association testing Genetic association was assessed by the transmission disequilibrium test (TDT) 24 for collections consisting of trios, as implemented by GENEHUNTER. 25 Association in cases and controls was determined by a standard w 2 test performed on a 2 Â 2 contingency table.
Combining analyses We computed a pooled estimate of the odds ratio (OR) using the logit method to combine data from different sources, and then derived a confidence interval for the OR as performed for a single 2 Â 2 table, as described previously. 26 
Results
In the 496 MS trios from the UK, the 620W allele frequency of 10% in the UK sample is similar to the reported allele frequency in North American populations of European descent. 1 -4,9 TDT analysis reveals that there is no evidence of association of the 620W allele in our MS samples, in fact, there is a nominally significant undertransmission of this allele (Table 1 , P ¼ 0.016). To derive a more accurate assessment of the role of this allele in MS using a familybased approach, we combined our data with the MS trio data collected by Begovich et al. 3 The latter 582 North
American MS trios of European ancestry from the UCSF collection represent the majority of the cases reported by Begovich et al, 3 and all cases fulfill McDonald criteria for MS. 27 The combined collection of 877 MS trios of European ancestry demonstrates no association of MS susceptibility with 620W (OR 0.84, 95% CI 0.66 -1.06) ( Table 1) . To incorporate all extant data on PTPN22 in MS, we also performed a pooled analysis that combines all of the trio data as well as three published case/control studies. 9, 17, 18 PTPN22
This analysis also failed to demonstrate association of MS susceptibility with PTPN22 620W (OR 0.95, 95% CI 0.81 -1.12) (Table 1) . Finally, a recent report suggests that the OR for an association of 620W with RA susceptibility in a large Swedish cohort is much greater in males (1.76) than females (1.19) (R. Plenge, personal communication). We therefore stratified the pooled trio data by gender but saw no significant evidence of association with MS susceptibility with either gender (data not shown).
To examine subjects with CD, we genotyped 169 trios as well as 249 cases and 207 control subjects collected in the province of Québec, Canada. The minor allele frequency of 0.08 for 620W in the CD trio samples is similar to those described in other populations of European descent, 1 -4,9,17,18 but the frequency of 0.04 in the case/control sample is less than expected. The combined TDT and case/ control analysis reveals no evidence of association of the 620W allele of PTPN22 with susceptibility for CD in our subject sample (OR 1.18, 95% CI 0.76 -1.84) ( Table 2) . A pooled analysis ( Table 2 ) that combines our data with those of the other significant studies of PTPN22 in CD 19, 20 similarly demonstrates no evidence of association between PTPN22 620W and susceptibility to CD (OR 1.04, 95% CI 0.80 -1.37). An analysis stratified by gender also did not reveal a significant association (data not shown). This pooled analysis of CD collections is substantial, but, given the modest OR's associated with the PTPN22 620W allele in other diseases, this analysis should not be considered as definitive in the evaluation of the role of PTPN22 in CD. The MS trio collection from the UK genotyped as part of this study is sample collection 1. The analysis of the UCSF MS trio samples (collection 2) used genotype data obtained from Dr J Oksenberg. 3 The frequency of the 1858T allele in the case and control subjects of collections 3 -5 was obtained from three published studies. 9, 17, 18 For example, the MADGC study reported 20T alleles among its 120 subjects with MS and 351T alleles among its 2064 control subjects. The pooled analysis uses the logit method to combine data from all five separate studies, as described in the Materials and methods section; as a result, healthy control subjects from collections 1 and 2 are not used when each of the three case/control logit values (collections 3 -5) are calculated. The frequency of the 1858T allele in the parents of the UK trio sample (1) is 0.098 and the frequency of the parents of the UCSF trio sample (2) is 0.101. The frequency of the 1858T allele in the parents of sample population (1) (trios from Québec) is 0.083. b The samples from the MADGC collections (40 cases of IBD) 9 are not added to the pooled analysis given the limited number of individuals with CD. The allele frequencies for sample collections (3) and (4) were obtained from published data. 19, 20 Discussion Reported estimates of the OR for 620W association with disease vary significantly from one study and one disease to another; however, an OR of 1.3 has clearly been observed for this allele in certain SLE and RA studies 4 The CD sample is smaller than the MS sample and has a somewhat lower frequency of the 620W allele; therefore, we cannot exclude the possibility that PTPN22 has a modest effect on susceptibility to CD. With the pooled analysis of 1019 cases of CD, we have an estimated 56% power to exclude an OR of 1.3 and 92% power to exclude an OR of 1.5 for the PTPN22 620W allele (assuming a multiplicative model of disease risk, allele frequency of 0.06, and an a of 0.05)(Genetic Power Calculator, http://statgen.iop.kc l.ac.uk/gpc/). 28 Thus, while evidence mounts that the 620W allele of PTPN22 may have an effect on susceptibility to T1D, RA, AIT, and SLE, the evidence so far points to a lack of association between this allele and susceptibility for either MS or CD. However, additional subjects from other collections will be needed to definitively exclude a role for the 620W allele of PTPN22 in these diseases.
